|1.||Reape, Kathleen Z: 1 article (07/2009)|
|2.||Shu, Haibin: 1 article (07/2009)|
|3.||Freedman, Murray: 1 article (07/2009)|
|4.||Kaunitz, Andrew M: 1 article (07/2009)|
|5.||Hait, Howard: 1 article (07/2009)|
|6.||Cavanagh, Lamont E: 1 article (04/2007)|
|7.||Carroll, Dana G: 1 article (04/2007)|
|8.||Marx, Phyllis: 1 article (01/2004)|
|9.||Schade, George: 1 article (01/2004)|
|10.||Nett, Robert: 1 article (01/2004)|
07/01/2009 - "The aim of this study was to evaluate low-dose synthetic conjugated estrogens A (SCE-A) cream administered twice weekly for the treatment of moderate to severe vulvovaginal atrophy (VVA) in a symptomatic postmenopausal population. "
01/20/2004 - "These results confirm the relatively rapid estrogenic effect and safety of a low-dose (0.3 mg/day) of slow-release SCE-A (Cenestin) in the treatment of vaginal atrophy in postmenopausal women."
01/20/2004 - "In this randomized, double-blind, multicenter clinical trial, 71 healthy postmenopausal women with vaginal atrophy (Vaginal Maturation Index < or =55) received either low-dose synthetic conjugated estrogens, A tablets (Cenestin) (SCE-A), 0.3 mg once daily, or placebo for 16 weeks. "
|1.||conjugated synthetic A estrogens (Cenestin)